GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Notes Receivable

Psyence Biomedical (Psyence Biomedical) Notes Receivable : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Notes Receivable?

Psyence Biomedical's Notes Receivable for the quarter that ended in Mar. 2023 was $0.00 Mil.


Psyence Biomedical Notes Receivable Historical Data

The historical data trend for Psyence Biomedical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Notes Receivable Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
Notes Receivable
- - -

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
Notes Receivable - - -

Psyence Biomedical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Psyence Biomedical Notes Receivable Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines